Brand-name medication guide
Learn what FoundAyo is, how oral orforglipron differs from injectable GLP-1 brands and compounded products, and how WellForm care and payment work.
FoundAyo is a once-daily oral GLP-1 prescription product, not an injection.
Orforglipron is not semaglutide or tirzepatide.
WellForm’s care fee does not include the medication.
The decision in plain language
FoundAyo is a once-daily oral GLP-1 prescription product. It is not injectable semaglutide or tirzepatide, and it should not be described as a compounded version of another brand.
FoundAyo identifies a specific FDA-approved prescription product.
Orforglipron is the active ingredient.
It is an oral tablet rather than an injection.
It is not Wegovy, Zepbound, Mounjaro, or compounded GLP-1 medication.
Current prescribing information—not assumptions from other GLP-1 products—controls FoundAyo use, instructions, risks, and contraindications.
Your care path
The physician evaluates fit for the specific oral product, explains the current pharmacy path, and follows response if it is prescribed.
Choose Ankeny or virtual care and tell us the option you want to discuss.
Review goals, history, current treatment, risks, and practical access.
Clarify the exact service or product, care fee, pharmacy path, and what is not included.
Monitor response, barriers, tolerability when relevant, and the next clinical or practical step.
Ready when you are
Oral tablet · Orforglipron, not semaglutide · Pharmacy paid separately
What happens next
The consultation, payment explanation, and follow-up plan remain visible before you commit.
Select the page-specific interest when you request an Ankeny or virtual visit.
Dr. Patrick Oben reviews clinical fit and explains the differences that matter.
Agree on the care setting, WellForm fee, and any separate pharmacy transaction.
Clinical fit
FoundAyo still requires a prescription-specific review of history, current medications, contraindications, and treatment goals.
Ongoing care
WellForm reviews response, tolerability, adherence, and whether the plan should continue or change.
Benefits and limits
Current prescribing information—not assumptions from other GLP-1 products—controls FoundAyo use, instructions, risks, and contraindications.
Compare your options
The class and brand pages explain how route, ingredient, and product identity differ.
Local, virtual, and payment
WellForm medical or support care is one transaction. A prescribed medication is generally a separate transaction with the dispensing pharmacy.
WellForm’s virtual medical-management fee. FoundAyo is paid separately to LillyDirect or the dispensing pharmacy.
WellForm’s in-person support fee. Depending on the selected medical weight-loss pathway, clinic support can include InBody scans, UltraSlim red-light support, Ballancer lymphatic care, Power Plate, nutrition guidance, and optional Quest laboratory work when clinically appropriate. FoundAyo is paid separately.
You pay LillyDirect, not WellForm. Current self-pay starts at $149 for 0.8 mg, $199 for 2.5 mg, and $299 for 5.5 mg and higher doses under Lilly’s published terms. Coverage, savings, supply, and a prescription are not guaranteed.
Before you request care
Oral tablet
Oral tablet · Orforglipron, not semaglutide · Pharmacy paid separately
Evidence and authority
Lilly and FDA materials define FoundAyo, orforglipron, dosage form, approved use, and safety information.
Official resources
Still comparing?
WellForm can clarify the page, visit type, and information to bring without promising treatment before evaluation.
FAQ
Clear answers to the questions most likely to affect your decision.
A responsible next step
Request a visit to review clinical fit, the current label, local or virtual follow-up, pharmacy fulfillment, and payment.
